Tesamorelin in the United States
EGRIFTA WR is an FDA-licensed tesamorelin prescription product under BLA 022505, with an 11.6 mg presentation and a defined HIV-lipodystrophy indication. The 10 mg research listings tracked here are not EGRIFTA WR, do not share its label, and do not inherit its approval or supply chain.
- Evidence lane
- Research price board
- Global identity
- US research-market identity with a separate FDA-licensed medicine record